San Diego-based Viking Therapeutics marked itself as a serious competitor inside the weight loss drug sector in February soon after revealing promising information from the mid-phase demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when provided being a weekly injection and in March the company un

San Diego-primarily based Viking Therapeutics marked itself as a serious competitor inside the weight loss drug marketplace in February just after revealing promising information from the mid-phase trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when specified as a weekly injection and in Mar